Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection

Abstract

Radioembolization is a safe and effective method for treating recurrent HCC following surgical resection, with prolonged TTP and promising survival outcomes.

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience

“…In comparison to the arterial occlusive macroembolic effects of TACE, the microembolic approach and beta radiation associated with Y90 provides a more versatile application of transarterial treatment, leading to acceptable outcomes for all stages of Barcelona Clinic Liver Cancer (BCLC) disease . For early stage A, Y90 has been used to successfully downstage tumors to liver transplantation (LT), hypertrophy the future liver remnant for potential resection, treat recurrences following resection, significantly prolong time to progression (TTP) compared with TACE, and represent an alternative to ablation for unablatable lesions . For stage B, Y90, which is performed in the outpatient setting, has demonstrated comparable survival yet superior quality of life (QoL) compared to TACE .…”

Sub‐Micrometer Au@PDA‐125I Particles as Theranostic Embolism Beads for Radiosensitization and SPECT/CT Monitoring

“…Additionally, radioactivity can be adjusted to fulfill the required dose of intra‐irradiation via adjusting the amount of 125 I. Furthermore, beam radiation type of intra‐irradiation can be changed via labeling or doping with other radionuclides (such as 90 Y, 125/131 I, and 103 Pd), which is a common way in designing multifunctional theranostic agents …”

Radiofrequency Ablation for Pediatric Recurrent Hepatocellular Carcinoma: A Single-center Experience

“…However, repeated surgery either salvage LT or re-resection might not be an option for children with RHCC who cannot tolerate surgical stress. Radiotherapy, such as Yttrium-90 transarterial radioembolization (Y90-TARE) and SBRT, has been reported in the treatment of RHCC [32,33]. For now, few studies have reported the use of Y90-TARE or SBRT in pediatric liver malignancy, which might be associated with radiation exposure, and the need of specialized equipment and technical expertise required for its safe use [34,35].…”